Source: Annual Congress 2006 - Established and experimental therapies for allergic asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Dewilde, P. Dale, F. Turk (Bussels, Belgium; London, United Kingdom; Basel, Switzerland). Cost effectiveness of omalizumab in Swedish asthma patients. Eur Respir J 2006; 28: Suppl. 50, 2569

Member's Comments

No comment yet.

Related content which might interest you: Cost analysis for patients with severe asthma receiving omalizumab treatment Source: International Congress 2019 – Clinical aspects of airway diseases Year: 2019 Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 The effectiveness of omalizumab in steroid-dependent asthma patients Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018 Year: 2019 Safety and efficacy of omalizumab in children with allergic asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011 Cost of asthma in patients treated with national asthma guideline in Turkey Source: Eur Respir J 2003; 22: Suppl. 45, 481s Year: 2003 Cost of asthma rescue/acute and allergy medications among asthmatic patients on controller therapy Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004 Cost effectiveness of bronchial thermoplasty for treatment of severe asthma patients in spain Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Economic costs of severe asthma in omalizumab-treated patients. FENOMA Study Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017 The eXpeRience registry: Monitoring the ‘real-world‘ effectiveness of omalizumab in allergic asthma Source: Annual Congress 2011 - Asthma management and response Year: 2011 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Cost implications for the introduction of omalizumab in to the management of severe chronic asthma in children Source: Eur Respir J 2006; 28: Suppl. 50, 481s Year: 2006 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Safety of omalizumab therapy in children with allergic asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Physician assessment of asthma control in patients receiving omalizumab in a real-world setting Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Long-term safety and efficacy of budesonide/formoterol in Japanese patients with asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting Source: International Congress 2017 – Asthma management Year: 2017 BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014